PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
                                   :
    SUNDREHAGEN et al.   :   Attention:
                                   :   PCT Legal Office
Serial No.:   10/539,797   :
                                   :
Filed: December 19, 2005   :
                                   :
For: CVD ASSAY   :

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

    This Supplemental Information Disclosure Statement is being submitted with thirteen additional references cited in prosecution and, more recently, during opposition of a case relating to a similar subject matter that Axis-Shield ASA is opposing.

    This Information Disclosure Statement along with references is submitted prior to the mailing date of the first Official Action on the merits received by Applicants in the above-identified application.

    The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.

<div style="text-align: right">

Respectfully submitted,
BACON & THOMAS, PLLC

By: Richard E. Fichter

Richard E. Fichter
Registration No. 26,382

</div>

625 Slaters Lane, 4th Fl.
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:cjw
Supplemental IDS.wpd

October 24, 2006

B/O Form PTO-1449		Atty. Docket Number COCK3001/REF			Serial Number 10/539,797		
U.S. Department of Commerce Patent and Trademark Office		Applicant Erling SUNDREHAGEN					
Information Disclosure Statement by Applicant		Filing Date December 19, 2005			Group 1641		

OCT 2 4 2006

U.S. Patent Documents

Examiner Initial		Document Number	Date	Patentee/Applicant	Class	Subclass	Filing Date if Appropriate
		4,287,202	09/01/1981	David F. Horrobin			

Foreign Patent Documents

Examiner Initial		Document Number	Publication Date	Country/Agency	Class	Subclass	Translation Yes	Translation No
		0 194 686 A1	09/17/1986	EP				
		60 139621 A	07/24/1985	JP (Abstract Only)			X	

Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

		F. Haverkate, et al., "C-reactive protein and cardiovascular disease", Fibrinolysis and Proteolysis, 1997, vol. 11, no. 1, pp. 133-134
		G. Di Minno, "Piastrine, Prostaglandine E Trombosi", Giorn. Arterioscler., vol. 3, no. 2, 1978, Database BIOSIS, AN 79:244445, pp. 101-109
		Lewis H. Kuller, et al., "Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study", American Journal of Epidemiology, 1996, vol. 144, no. 6, pp. 537-547
		Frits Haverkate, et al., "Production of C-reactive protein and risk of coronary events in stable and unstable angina", The Lancet, February 15, 1997, vol. 349, pp. 462-466
		Shih-Jen Hwang, PhD., et al., "Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atheroschlerosis and Incident Coronary Heart Disease Cases - The Atherosclerosis Risk In Communities (ARIC) Study", Circulation, December 16, 1997, vol. 96, no. 12, pp. 4219-4225
		Simon G. Thompson, et al., "Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris", The New England Journal of Medicine, March 9, 1995, vol. 332, no. 10, pp. 635-641
		Paul M. Ridker, M.D., et al., "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men", The New England Journal of Medicine, April 3, 1997, vol. 336, no. 14, pp. 973-979
		JoAnn E. Manson, MD, et al., "A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women", JAMA, July 24-31, 1991, vol. 266, no. 4, pp. 521-527
		Multiple Risk Factor Intervention Trial Research Group, "Multiple Risk Factor Intervention Trial - Risk Factor Changes and Mortality Results", JAMA, September 24, 1982, vol. 248, no. 12, pp. 1465-1477
		Steering Committee of the Physicians' Health Study Research Group, "Final Report on the Aspirin Component of the Ongoing Physicians' Health Study", The New England Journal of Medicine, July 20, 1989, vol. 321, no. 3, pp. 129-135

Examiner	Date Considered

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.